Private Market Stock Spotlight-Open Evidence-“CHAT-GPT For Doctor’s

OpenEvidence is a private, hyper‑growth “ChatGPT for doctors” that has quietly become one of the most important AI platforms in medicine, with metrics and backing that now put it firmly on the G.L.A TOP PRE-IPO List.

What OpenEvidence Is And What Problem It Solves

OpenEvidence is an AI‑powered medical search and clinical decision‑support platform built specifically for physicians and other licensed clinicians. Doctors ask natural‑language questions (“What’s the best second‑line therapy for metastatic NSCLC with this mutation?”) and get immediate answers grounded in peer‑reviewed evidence—complete with citations to journals like The New England Journal of Medicine, JAMA, NCCN guidelines, and other top‑tier sources.

The core problem it attacks is information overload and outdated knowledge in medicine: no human can keep up with the volume and velocity of new clinical research, nor cross‑reference it against individual patient context in real time. OpenEvidence’s models continuously ingest, index, and reason over the medical literature, then surface synthesized, evidence‑based answers at the point of care so clinicians can practice true evidence‑based medicine rather than relying on memory, habit, or outdated guidelines.

Unlike general‑purpose chatbots, OpenEvidence operates inside a “walled garden” of fully licensed medical content, including NEJM, JAMA, NCCN, and major society guidelines, and is architected to show its references and avoid hallucinations in clinical contexts. This makes it far more suitable for high‑stakes medical decisions than consumer LLMs that scrape the open web.

Business Model, Growth, And Traction

OpenEvidence’s go‑to‑market is deceptively simple: free, high‑quality access for verified clinicians, then monetization through pharma and life‑science advertising and partnerships—without selling raw query data or using patient data to train models. The platform has become the most widely used medical search and AI application among U.S. clinicians, with more than 40% of U.S. physicians reportedly using it daily for clinical decisions.

Key growth and business milestones:

• Usage: OpenEvidence is described as the “fastest‑growing clinical decision support platform in the United States” and “the most widely used medical search engine among U.S. clinicians.”p

• Revenue: Recent data pegs OpenEvidence at roughly a $100M revenue run‑rate, primarily from pharma advertising and enterprise partnerships, giving it real top‑line at a relatively early stage.

• Product integrations: The team is integrating directly into EHR workflows at oncology and specialty groups, surfacing evidence proactively instead of waiting for doctors to ask questions.

In addition to the core physician app (available on iOS and web), OpenEvidence is building deeper integrations with major publishers and clinical tools, such as Elsevier’s ClinicalKey AI, to become the default evidence layer beneath next‑generation clinical decision‑support systems.

Founder, Backers, And Funding / Valuation History

OpenEvidence was founded by Daniel Nadler (and co‑founder Zachary Ziegler) around 2021–2022, emerging out of the Mayo Clinic Platform Accelerate program. Nadler is a serial entrepreneur with a history of building data‑intensive systems, and here he’s gone all‑in on the thesis that the real bottleneck in medicine is evidence retrieval and synthesis at the bedside.

On the capital side, OpenEvidence has quickly become one of the most heavily funded private AI medical platforms:

• Early support: Backed by Sequoia and Google (GV), and closely tied into Mayo Clinic’s innovation ecosystem.

• Series B (July 2025): $210M Series B at a $3.5B valuation, co‑led by GV and Kleiner Perkins, taking total funding past $300M.a1

• Series C / later funding (late 2025): A subsequent round reported by The Information and highlighted by Access IPOs pegged the valuation at roughly $12B, with the round transacting at around $252 per share.a

• Total funding: Some trackers now estimate total capital raised around $700M across multiple rounds, including a later Series D.

As of early 2026, OpenEvidence is widely cited as a $12B‑valued private company, with some secondary‑market implied valuations approaching the low‑$20B range as liquidity venues re‑price shares.

Private‑Market Price Action (Last ~2 Years)

Pre‑IPO secondary venues give a granular picture of how quickly OpenEvidence has re‑rated:

• 2024: OpenEvidence is still under the radar with limited secondary visibility; shares reportedly trade in single‑digit or low‑double‑digit dollars on very thin volume.

• Mid‑2025: Following the $210M Series B at a $3.5B valuation, implied secondary prices begin to climb, reflecting rapid adoption in U.S. hospitals and the “ChatGPT for doctors” narrative gaining traction in mainstream media.linkedin+2

• Late 2025 / early 2026:The Series C (and subsequent rounds) at a $12B valuation push primary pricing to roughly $252 per share, with secondary platforms soon quoting significantly higher marks as demand outstrips supply.accessipos+2

• Mid‑2026: Nasdaq Private Market reports an estimated OpenEvidence price per share of about $518 as of June 17, 2026, representing a gain of roughly 1,600% from some earlier reference points; another venue (Hiive, via StockAnalysis) shows recent trades around $460–$460+ per share, with a 52‑week high above $510 and a theoretical 1‑year return printed at over 46,000%.

So in approximately 12–18 months, OpenEvidence has gone from high‑single or low‑double‑digit pricing to the high‑hundreds per share in secondaries, with an implied valuation jumping from $3.5B to over $20B in some estimates. The current private‑market mark (~$460–520 per share) corresponds to an implied valuation well north of the last disclosed $12B round, suggesting intense demand for pre‑IPO exposure and tightly constrained supply.

OpenEvidence remains private; there is no public ticker or IPO filing yet, and access is typically via SPVs, secondary platforms, or curated allocations for accredited investors.

Product, Moat, And TAM

Product And Differentiation

Three core design choices give OpenEvidence a defensible position against generic LLMs:

• Medical‑only focus: The models and retrieval stack are optimized exclusively for medicine, not general internet questions.

• Fully licensed, walled‑garden content: OpenEvidence licenses full‑text and multimedia content from NEJM, JAMA, NCCN, major specialty societies, and other top publishers, ensuring that answers are built on high‑quality, peer‑reviewed evidence.

• Evidence‑first UX: Every answer is accompanied by explicit citations and links, and the system is designed to aggregate, synthesize, and visualize clinically relevant evidence, not just generate plausible prose.

These choices are hard to replicate quickly: negotiating publisher licenses, building society partnerships, and integrating within clinical workflows takes years and deep domain trust.

TAM

The total addressable market spans:

• Clinical decision support and medical search for physicians worldwide

• Pharma and life‑science advertising and education in a highly targeted, high‑intent context

• Enterprise/EHR licensing for hospitals, health systems, and payors

OpenEvidence already serves more than 40% of U.S. physicians on at least a monthly basis and is the most widely used medical search engine among U.S. clinicians. That gives it a credible path to capture a meaningful share of a global clinical‑decision‑support and health‑AI TAM that is likely in the tens of billions annually when you combine software, workflow tools, and pharma/biotech information spend.

G.L.A GAUNTLET: OpenEvidence Scorecard

1) Scale And Predictability (≥$2B Market Cap, ≥$100M Revenue)

• Valuation: OpenEvidence meets and far exceeds the $2B bar; it is marked around $12B in late‑2025/early‑2026 primary rounds, with some secondary estimates above $20B implied.

• Revenue: Estimated revenue run‑rate is around $100M, putting it at the threshold of the G.L.A minimum despite still being early in its S‑curve.

Gauntlet view: Clear pass on scale; revenue is still emerging but already at the lower bound of the G.L.A bar.

2) Visionary Founders / Innovation Focus

Founder Daniel Nadler is pursuing a bold, narrowly scoped vision: organize global medical knowledge and put it directly into the clinical workflow so every decision is truly evidence‑based. The decision to focus solely on medicine, license the world’s most prestigious journals, and refuse to train on patient queries or sell raw data shows an unusually principled and mission‑driven approach in a frothy AI landscape.

Gauntlet view: Strong pass on visionary founder and innovation.

3) “Must‑Have” Product

For many physicians, OpenEvidence has already become a default tool at the point of care, with daily usage by a large share of the U.S. clinician base. In fields like oncology and cardiology, being able to instantly surface the latest trial data and guideline updates when facing a complex case is the difference between guesswork and precision.

As more health systems integrate OpenEvidence directly into their EHRs, it migrates from “search tool” to “embedded co‑pilot,” further cementing its must‑have status.

Gauntlet view: High; for modern physicians, especially specialists, OpenEvidence is on track to be as essential as UpToDate or an EHR login.

4) Hyper Growth And Balance Sheet / FCF

User growth, valuation, and secondary price action all signal hyper‑growth: a $3.5B valuation in mid‑2025, a $12B mark later that year, and implied valuations above $20B a year later is a steep curve even by AI standards. With ~$700M in total funding and strong revenue momentum, OpenEvidence is positioned with a fortress‑like balance sheet for a software‑heavy business, even if it still runs FCF negative while investing heavily in product and go‑to‑market.

Gauntlet view: Strong pass on hyper‑growth posture and capital base; free‑cash‑flow positivity is a medium‑term milestone but not current.

5) Huge TAM

Nearly every clinical encounter—worldwide—is a potential touchpoint for evidence‑based AI support; that alone implies a massive TAM. Layer in pharma advertising budgets, CME/education spend, and hospital software contracts, and you have a multi‑tens‑of‑billions TAM for a category‑defining platform.

Gauntlet view: Clear pass.

6) Impenetrable Moat

OpenEvidence’s moat is multi‑layered:

• Deep content licensing with leading journals and societies (NEJM, JAMA, NCCN, ACC, etc.) that competitors cannot quickly replicate.

• Network effects from clinician adoption: once 40%+ of U.S. physicians use a given platform daily, it becomes the default place to publish, advertise, and integrate.

• Technical integration into EHRs and clinical workflows, increasing switching costs over time.

Gauntlet view: Very strong; this is as close as it gets to an emerging “operating system” for evidence‑based medicine.

7) Risk/Reward Profile

Upside:

• If OpenEvidence cements itself as the global default medical AI co‑pilot, a $20B+ valuation today could still be an early innings mark, especially over a 10‑year horizon.

• As revenue mix matures from ads to higher‑margin enterprise/EHR contracts, operating leverage could be substantial.

• Strategic value to big tech and major health IT incumbents (Epic, UnitedHealth/Optum, etc.) makes a premium acquisition a credible scenario as well.

Risks:

• Regulatory and liability risk if AI‑supported decisions lead to adverse outcomes and plaintiffs or regulators target the decision‑support layer.

• Platform risk: heavy reliance on relationships with publishers and societies; if licensing terms or competitive alignments shift, content access could be challenged.

• Valuation risk: at implied $20B+ and a ~120× price‑to‑sales multiple, the market is already pricing in aggressive growth; any slowdown or competitive narrative could compress multiples.

Gauntlet view: High‑quality risk with rich but not irrational reward if OpenEvidence becomes the canonical “AI layer for medicine”; risks are real but aligned with G.L.A’s tolerance.

8) Solving Major Societal Problems

OpenEvidence is directly attacking two of the biggest problems in healthcare: variable care quality due to uneven knowledge, and the inability to operationalize new evidence quickly and consistently across millions of clinicians. By making up‑to‑date, peer‑reviewed evidence available at the point of care, it aims to flatten the quality curve of medicine globally—arguably one of the highest‑leverage problems you can work on.

Gauntlet view: A textbook example of “solve big societal problems, earn big long‑term returns.”

9) Tier‑One Investors

The cap table includes Sequoia, Google Ventures (GV), Kleiner Perkins, and strategic alignment with Mayo Clinic and major publishers—essentially a who’s who of top‑tier venture and health‑care institutional players. These investors bring not just capital but distribution, regulatory expertise, and deep industry networks.

Gauntlet view: Strong pass.

10) Misunderstood / Underappreciated

Public markets still tend to think of “AI in healthcare” as either generic LLMs or niche diagnostic tools; the idea of a ubiquitous, evidence‑layer OS for medicine is under‑modeled in most public frameworks. In private markets, the rapid appreciation in secondaries shows that sophisticated investors are catching on, but the story is still largely invisible to mainstream Wall Street because OpenEvidence is not yet public.research.contrary+6

Gauntlet view: Fits squarely in the “Wall Street doesn’t get it yet” bucket that has historically produced outlier returns.

Potential Exit Paths

1. Blockbuster IPO
   With scale, growth, and brand among clinicians already in place, OpenEvidence is a natural candidate for a large, high‑profile IPO once public markets normalize for AI names. A successful listing could easily price in the higher double‑digit billions, with long‑term upside if it grows into a category‑defining platform.

2. Strategic Acquisition
   OpenEvidence is strategically valuable to multiple classes of buyers: big tech (Alphabet, Microsoft, Amazon), major health IT platforms, and large payors/providers wanting to own the evidence layer. A competitive bidding environment could create a significant liquidity event for late‑stage private holders, though at the cost of capping multi‑decade compounding.

3. Long‑Term Private Compounding / Late‑Stage Rounds
   Given the depth of late‑stage capital and strategic interest, OpenEvidence may choose to stay private longer, raising additional growth rounds while deepening its moat and revenue base before eventually going public. In that scenario, accredited investors’ main liquidity path for the next few years will be secondaries and structured vehicles.

Coach Kyle’s 2 CENTS: OpenEvidence looks like a rare, late‑stage private asset that already clears the size, revenue, and moat thresholds, squarely solves a major societal problem, and still has a long runway as the de‑facto AI operating system for global medicine—albeit with valuation and regulatory risks you must size for carefully.